Scottsdale Magnesium Study

MagSRT™, a time-release Magnesium supplement from Jigsaw Health, was tested vs. Placebo in a human clinical trial of 91 people.

Results of the Scottsdale Magnesium Study were published by the highly-acclaimed, peer-reviewed Journal of The American College of Nutrition (JACN) in 2018. (Coming out in print in the May/June 2018 edition.)

Summary of Scottsdale Magnesium Study

Scottsdale Magnesium Study - MagSRT Increased Serum Magnesium

Scottsdale Magnesium Study - MagSRT Increased RBC Magnesium

Scottsdale Magnesium Study - MagSRT Decreased Magnesium Deficiency Symptoms

RESULTS: More than 75% of trial participants presented with suboptimal serum and RBC magnesium status at baseline, while the magnesium status questionnaire predicted 100% of participants to have suboptimal magnesium status. MagSRT™ was well tolerated by 91% of magnesium intervention participants. RBC magnesium increased 6% and 30% over 30 and 90 days, respectively, suggesting magnesium absorption and uptake into red blood cells over time. Overall symptomatology, assessed through a magnesium status questionnaire, improved 28% over 30 days and 63% over 90 days.

CONCLUSION: A standard adult clinical population presented with both qualitative and quantitative evidence of compromised magnesium status at the beginning of the trial. Supplementation with MagSRT™, a timed-release dimagnesium malate supplement containing vitamins B6, B12, and folate, for at least 30 days significantly improved magnesium status symptoms and increased RBC magnesium with minimal gastrointestinal symptoms.

Scottsdale Magnesium Study - Summary of Findings

Download Scottsdale Magnesium Study Summary (PDF)